Semax
ACTH(4–7)-Pro-Gly-Pro
Semax is an ACTH-related investigational peptide. The captured human report concerns stroke rehabilitation; it demonstrates neither enhancement in healthy people nor effects of N-acetylated variants.
Peptipedia explains research and prescribing information. It does not replace medical advice and is not an invitation to use a substance.
Identity not confirmed
The name may refer to different substance or product forms.
The parent ACTH(4–7)-Pro-Gly-Pro sequence is defined, but the free base, acetate salt and N-acetylated variants are not interchangeable. A product’s specific form requires analytical confirmation.
Research areas
Evidence matrix
- Molecular identity
- Partially clarified
The parent ACTH(4–7)-Pro-Gly-Pro sequence is defined, but the free base, acetate salt and N-acetylated variants are not interchangeable. A product’s specific form requires analytical confirmation.
- Human research
- Limited
- Replication
- Single research group
- Clinical endpoints
- Symptom- or function-related
- Safety
- Not adequately studied
- Approval
- No documented approval
The dimensions are presented separately and are not combined into an overall score.
What the source shows
The report compared groups with and without Semax among 110 patients at different rehabilitation stages and reported functional improvements; the abstract does not establish clear randomized, blinded allocation.
- The efficacy of Semax in the treatment of patients at different stages of ischemic strokeHuman study2018
Gusev EI et al.
Accessed:
Research gaps
- ·Clinical evidence is limited, difficult to confirm independently and cannot be transferred to other molecular forms or indications.
- ·Short profile: not a complete benefit–risk assessment. Unlisted contraindications and interactions are not adequately established in this profile; missing information does not establish safety.
Mechanism
Researchers examined BDNF levels and functional recovery. An association with BDNF does not establish a clinical mechanism.
- The efficacy of Semax in the treatment of patients at different stages of ischemic strokeHuman study2018
Gusev EI et al.
Accessed:
Study protocols
No sufficiently supported, exactly citable study protocols are available.
Calculator
Arithmetic based only on your entries. Not a dose or use recommendation.
Reported adverse effects
- ·Evidence is insufficient; absence of data is not evidence of safety. FDA found no clinical assessments of immunogenicity or aggregation and identifies related risks from aggregates and impurities for intranasal and injectable forms.
Contraindications and warnings
No reviewed information on this point has been recorded here yet. This does not mean there are no risks or contraindications.
Interactions
No reviewed information on this point has been recorded here yet. This does not mean there are no risks or contraindications.
Research gaps
- ·Clinical evidence is limited, difficult to confirm independently and cannot be transferred to other molecular forms or indications.
- ·Short profile: not a complete benefit–risk assessment. Unlisted contraindications and interactions are not adequately established in this profile; missing information does not establish safety.
- FDA evaluation of Semax-related bulk drug substances (free base and acetate)Regulatory source2026
U.S. Food and Drug Administration
Accessed:
Sources
Sources checked: · Version 3
- The efficacy of Semax in the treatment of patients at different stages of ischemic strokeHuman study2018
Gusev EI et al.
Accessed:
- FDA evaluation of Semax-related bulk drug substances (free base and acetate)Regulatory source2026
U.S. Food and Drug Administration
Accessed: